Edward F. Amer

Ed Amer is a partner in Goodwin's Private Equity group, advising private equity sponsors, growth equity investors, venture capital firms, portfolio companies, and operating businesses on a wide range of sophisticated transactions. His practice includes buy-side and sell-side acquisitions, divestitures, carve-outs, strategic partnerships, joint ventures, growth equity investments, equity financings, and general corporate matters.

Ed has significant experience representing companies and investors in the healthcare and life sciences sectors, working with clients at every stage of the business lifecycle (from growth-stage companies pursuing strategic investments to later-stage companies executing complex acquisition strategies), and preparing for future liquidity events. In addition to his transactional practice, Ed provides ongoing strategic counsel on corporate governance, commercial relationships, and other business matters that arise as companies scale. He regularly counsels management teams, boards of directors, and investors on transactions that support expansion, strengthen market position, and create long-term value. Ed’s practical, business-oriented approach and experience representing both investors and operating companies allow him to anticipate issues, navigate complex negotiations, and help clients execute transactions efficiently while remaining focused on their broader business objectives.

Before pursuing a legal career, Ed worked as a lighting technician in the motion picture industry, experience that shaped his collaborative approach to client service, and reinforced the importance of teamwork, problem-solving, and delivering results under demanding deadlines.

Ed’s recent representations include:

• Ampersand Capital Partners in its acquisition, together with GHO Capital, of Avid Bioservices, a CDMO focused on the development and CGMP manufacturing of biologics. 
• Flagship Pioneering, a biotechnology company that invests and builds platform companies, in Innovation Supply Chain partnerships with each of Pfizer, Novo Nordisk and GSK.
• Mission BioCapital, an early-stage life science investment fund, in multiple investments and multi-asset company formation projects.
• Ampersand Capital Partners in its investments in Resolian, a CRO specializing in advanced bioanalytical research services for both small and large molecule drugs, and Vantage MedTech, a leading provider of design, development and regulatory services to the medical device industry.
• InterWell Health, a physician-centric organization focused on supporting the renal patient population across the full continuum of care, in its initial formation, equity financings, and subsequent merger with Fresenius Health Partners and Cricket Health.
• Pairwise Plants, a company applying gene editing technology in the agricultural space, in collaborations with Corteva and Sun World and general corporate representation.
• Confluent Medical, a leading materials science, development, and manufacturing partner to medical device manufacturers, in the sale of a majority ownership stake to TPG Capital.
• Erbi Biosystems, a developer of micro-bioreactor platform technology, in its sale to MillaporeSigma, the North American life science business of Merck.
• Symeres, a Netherlands-headquartered CRO/CDMO and Keensight Capital portfolio company, in its acquisitions of Organix, a specialized organic chemistry services provider, and Exemplify BioPharma, a CMC chemistry service provider.
• Arranta Bio, a CDMO focused on providing development and commercialization services for therapeutic companies targeting the human microbiome, in its initial financing, strategic partnership with Thermo Fisher Scientific, and acquisition of Captozyme.
• Shields Health Solutions, a specialty pharmacy integrator and care provider for hospitals, in connection with equity investments by Welsh, Carson, Anderson & Stowe and Walgreens, and a subsequent majority recapitalization and ultimate acquisition by Walgreens. 
• Cerevel Therapeutics, a life science company focused on neuroscience disease, in a royalty monetization transaction with NovaQuest and Bain Capital.
• ModeX Therapeutics, a biotechnology company focused on immune therapies for cancer and infectious diseases, in its acquisition by OPKO Health.
• Repligen Corporation, a life sciences company that develops and commercializes bioprocessing technologies and systems, in its acquisition of Avitide, a market leader in affinity ligand discovery and development.
• Teva Pharmaceuticals in the sale of its Plan B One Stop product and related assets to Foundation Consumer Healthcare.
• Ultragenyx, a biopharmaceutical company focused on rare diseases, in its acquisition of an exclusive option to acquire GeneTx, a start-up biotechnology company focused on Angelman syndrome, and the subsequent exercise of such option.
• Abide Therapeutics, a drug development company focused on CNS indications, in its acquisition by Lundbeck.
• Avista Pharma Solutions, a contract provider of drug substance, drug product and analytical services, in its sale to Cambrex Corporation.
• ZOLL Medical in its acquisitions of Payor Logic, a provider of RCM software solutions for the healthcare industry, and Golden Hour Data Systems, a provider of patient charting and RCM services in the EMS market.
• Confluent Medical in its acquisitions of Interface Catheter Solutions, a contract manufacturer of balloon catheter systems, and Corpus Medical, a contract developer and manufacturer of interventional medical devices.
• MPI research, an early-stage drug development CRO, in its sale to Avista Capital Partners.
• Florida Biologix in its merger with Brammer Biopharmaceuticals, forming Brammer Bio, a cell and gene therapy biologics CDMO, and Brammer Bio in its acquisition of a biologics manufacturing facility from Biogen.
• Ampersand Capital Partners and 1315 Capital in their acquisition of Genoptix, an oncology diagnostics company, from Novartis, and in the subsequent sale of Genoptix to NeoGenomics Laboratories.
• Haven Healthcare, the healthcare delivery startup founded by Amazon, Berkshire Hathaway and J.P. Morgan and led by Atul Gawande, in general corporate matters.

Ed previously served as Co-Chair of the M&A Committee of the Business Transaction Section of the Boston Bar Association.

In law school, Ed served on the Boston College Law Review and was a member of the Order of the Coif.